Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab + Pembrolizumab vs Docetaxel in PD-L1+ Advanced NSCLC
NCT06635824Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of acasunlimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genmab. Primary endpoint: Overall Survival at 5 years. Started Nov 2024; status: active, not recruiting.
02
Drugs
acasunlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06635824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635824.